Drug Utilization Review Board
Minutes Draft

Name of Meeting: Drug Utilization Review Board
Date of Meeting: November 12, 2015
Length of Meeting: 1 hour and 53 minutes
Location of Meeting: DMAS Board Room 13th Floor

Members Present:
Randy Ferrance, MD, Chair
Avtar Dhillon, MD
Seth Brant, MD
Jonathan Evans, MD
Bill Rock, PharmD, Vice Chair
Denese Gomes, NP
Michele Thomas, PharmD
Wendy Nash, PharmD
Sandra Dawson, RPh

Members Not Present:
Rhonda Bass, MD
Jamie Haight, RPh

DMAS Attendees:
Donna Proffitt, RPh, Pharmacy Program Manager
Rachel Cain, PharmD
Tyrone Wall, CPhT
Vanea Preston, Program Integrity
Dacia Henry, Program Integrity

Contractors:
Donna Johnson, PharmD, Clinical Pharmacy Manager, Xerox
Tina Carter, CPhT, Pharmacy Technician
Sandy Kapur, PharmD, Xerox

Vendors:
Debbie Moody, RPh, Magellan Health Services
Nancy Eldin, PharmD, Magellan Health Services

Visitors:
Ken Jennings, BMS
Anne Masich, VCU Pharmacy Student
MarkWyche, VCU Pharmacy Student
Jason Richardson, Allergan
Gene Hughes, Novartis

Call to Order and Introductions
Dr. Ferrance called the meeting to order at 2:07pm.

Minutes—August 20, 2015
Meeting minutes were reviewed and approved.

New Drugs

Addyi™ (flibanserin) – Dr. Johnson did not present drug information or service authorization criteria recommendations because this drug is not covered as a pharmacy benefit per state regulations. The Board seconded and approved.

Odomzo® (sonidegib) – Dr. Johnson presented the drug information and service authorization criteria recommendations. The motion was made to accept the criteria as written for both Odomzo® and Erivedge™ with a change of SA approval to 12 months for each. The Board seconded and approved criteria.

New Drugs: PDL-eligible; physician-administered injectables. Daklinza™ is now preferred as of January 2016.

Service Authorizations

No updates needed

Topics for Discussion

(1) Analysis of Compounded Medications – Dr. Johnson reviewed the report provided in the DUR Board binder. Dr. Evans recommended all compounds should require a Service Authorization (SA) for the reasons of sterility, safety and fraud. The Board agreed to conduct further research on compounded medications by gathering additional information such as: reviewing patient profiles of those on topical analgesics, check for billing appropriateness, review prescribers and their specialty, obtain DMAS definition of compounding, ask other states what they are doing with compounds, and refresh data for more current utilization reports. The motion was made and approved to establish a subcommittee to review before the next DUR Board meeting.
(2) Morphine Equivalent Dosing for Narcotics – A motion was made and approved to review quantity limits and dose optimization for narcotics in March.
(3) Synagis utilization – Dr. Johnson reviewed the report provided in the DUR Board binder.
(4) New DUR Quarterly Newsletter - recommendations were made to add link to SA website and describe DUR Board role and function in the newsletter.

Reports

ProDUR and RetroDUR –Dr. Johnson reviewed the reports provided in the DUR Board binder.

Utilization Analysis Reports – Dr. Johnson reviewed the Top 25 Drugs Ranked by Claim Count, by Payment Amount and the Cost of Utilization Analysis by Drug Type provided in the DUR Board binder.

Top Diagnoses by Age – Dr. Johnson reviewed the top Diagnoses by Age for all ages provided in the DUR Board binder.

AAP Report

Dr. Johnson reviewed the report provided in the DUR Board binder. The request was made for a run chart and larger font.

Announcements

Dr. Cain announced the following:

(1) As of 2014, Polypharmacy threshold – the DUR Board is no longer legislatively required to review members receiving 9 plus prescriptions per month.
(2) DMAS has an opening for a Medical Director.
(3) Donna Johnson has given her resignation to Xerox and her last day is December 4, 2015.

Bylaws tabled until March 2016.

Meeting was adjourned at 4:00 pm.

Next DUR Board meeting is scheduled for March 10, 2016. Subsequent DUR Board meeting dates in 2016 were approved for May 12th, August 11, and November 10th.